Cagrilintide's dosing interval and the pharmacokinetics behind it posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Collapsed as off-topic by two members at trust level 3 or above
Post #59 is the version of this I will quote in future. One addition.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
I would call that likely rather than established.
The pharmacokinetics support weekly dosing comfortably. What the pharmacokinetics do not tell you is the tolerable escalation rate, and that is the practical constraint in every published protocol.
Nothing to add on the substance. Thank you for taking the question at face value.
Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.
For what it is worth, the same held on the two occasions I checked.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
Adding it because I spent an afternoon working it out and nobody should have to twice.
Answering the question post #63 raises rather than the one it answers.
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
Noted, and I have changed what I was going to do on the strength of it.
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.
Post #70 is the version of this I will quote in future. One addition.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
None of the above is medical advice and I am not qualified to give any.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
The honest answer is that it depends, and here is what it depends on.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
Collapsed as off-topic by two members at trust level 3 or above
Useful. I have added it to my own notes with the date on it.
Confirming post #73 from a second method, which matters more than confirming it from a second person.
Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.
I had written a reply contradicting post #72 and deleted it. Here is what survived.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.
The general case is well covered; this is the awkward specific one.
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
Noted, and thank you for writing it out rather than summarising it.
Post #76 and I disagree about the size of the effect, not about the direction.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
On post #77 — agreed on the reasoning, with one qualification.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
Reporting the observation and leaving the explanation open deliberately.
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
I would treat the number as indicative rather than as a measurement.
The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.
Happy to be the one who is wrong here if it settles the question.
This follows post #85 rather than contradicting it.
On dosing intervals: the long-acting design supports weekly administration, and the escalation schedules in the published trials are gentler than the compound's potency alone would suggest. Tolerability is the constraint.
That is where I would start, not where I would stop.
Coming back to post #85, because the follow-up matters more than the original answer.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
Collapsed as off-topic by two members at trust level 3 or above
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.
Anyone reading a purity result for cagrilintide should know that its aggregation behaviour makes sample handling matter more than usual. A result on a sample that was warmed and cooled several times in transit is measuring the transit as much as the material.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
A weak preference rather than a position.